Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. (TNGX) is a clinical-stage biotechnology company pioneering precision oncology solutions through innovative target discovery and therapeutic development. This page provides authorized updates on their research programs, clinical trials, and strategic initiatives in cancer treatment innovation.
Investors and researchers will find verified information about TNGX's pipeline progress, including PRMT5 inhibitor developments for CNS/non-CNS cancers and discontinued programs like TNG348. All content undergoes strict verification to ensure accuracy in reporting scientific milestones and regulatory updates.
Key coverage areas include clinical trial phases, research collaborations, peer-reviewed study publications, and corporate developments. The resource is particularly valuable for tracking therapies addressing tumor suppressor gene restoration and immune evasion mechanisms.
Bookmark this page for real-time updates on Tango Therapeutics' work in CRISPR-enabled drug discovery and their mission to transform cancer treatment paradigms through precision medicine approaches.
Tango Therapeutics (NASDAQ: TNGX) announced the approval of a Clinical Trial Application for TNG908, a PRMT5 inhibitor, by France's ANSM. The company introduced TNG260, targeting STK11-mutant cancers, and TNG348 as a USP1 inhibitor for BRCA1/2-mutant cancers. Aaron Weitzman, M.D., was appointed Chief Medical Officer. Financially, Tango reported Q3 2022 results: collaboration revenue of $6.9 million, a net loss of $29.1 million, and $393.3 million in cash, expected to fund operations into 2025, despite increased R&D and G&A expenses.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company, announced that its CEO, Barbara Weber, will participate in two investor conferences this November. The first event is the H.C. Wainwright 3rd Annual Precision Oncology Conference on November 14 at 11:00 AM ET, followed by the Jefferies London Healthcare Conference on November 15 at 10:20 AM GMT. Both presentations will be available via live webcast on the company’s website, with replays accessible for 90 days.
Tango Therapeutics (NASDAQ: TNGX) announced the selection of three abstracts for poster presentations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, scheduled from October 26-28, 2022. The posters will cover the characterization and potential of TNG908 and TNG462, both designed to target MTAP-deleted cancers. Notably, TNG908 is highlighted as a brain-penetrant inhibitor, while TNG462 aims to be a best-in-class option. These presentations showcase Tango's focus on precision cancer therapies.
Tango Therapeutics announced the preclinical development of TNG260, a novel CoREST deacetylase inhibitor targeting STK11-mutant cancers. Presenting three abstracts at the 37th Annual Meeting of the Society for Immunotherapy of Cancer from November 8-12, 2022, the company aims to demonstrate how TNG260 potentially overcomes immune evasion associated with STK11 mutations, common in non-small cell lung cancers. Plans include submitting an IND application in H1 2023, highlighting the innovative approach to cancer treatment.
Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company focused on precision cancer medicines, announced that its CEO, Barbara Weber, M.D., will participate in the H.C. Wainwright 24th Annual Global Investment Conference. The presentation will be available on-demand starting September 12, 2022, at 7:00 AM ET. An archived replay will be accessible on the company’s website for approximately 90 days post-event. Tango Therapeutics specializes in discovering novel drug targets, emphasizing precision oncology for cancer treatment.
Tango Therapeutics reported its Q2 2022 financial results, holding $416.4 million in cash. The company is advancing TNG908, an MTA-cooperative PRMT5 inhibitor, in a Phase 1/2 trial for treating MTAP-deleted solid tumors, having received Orphan Drug Designation from the FDA for malignant peripheral nerve sheath tumors. Collaboration revenue decreased to $5.8 million, while research and development expenses rose to $23.7 million. The net loss for Q2 2022 increased to $24.9 million, or $0.28 per share, compared to a loss of $4.5 million, or $0.09 per share, in Q2 2021.
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced that its CEO, Barbara Weber, M.D., will participate in a virtual panel on synthetic lethality in cancer therapeutics at the 13th Annual Wedbush PacGrow Healthcare Conference on August 9 at 12:00 PM ET. The event will be accessible via a live webcast on the company's website and will remain available for replay for 30 days after the presentation. Tango is focused on advancing precision cancer therapies through innovative drug targets and leveraging synthetic lethality.
Tango Therapeutics (TNGX) announced its inclusion in the Russell 2000, Russell 3000, and Russell Microcap Indexes, effective June 24, 2022. This addition reflects increasing investor interest as the company progresses its lead asset, TNG908, into clinical trials and expands its pipeline with new candidates. According to CEO Barbara Weber, this visibility could attract new investors, enhancing the company's market position and potential growth opportunities.
Tango Therapeutics, a biotechnology firm focused on precision cancer medicines, will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 11:20 AM PT in Rancho Palos Verdes, CA. Investors can access a live webcast on the company's website under the 'Events & Presentations' section, with a replay available for 30 days afterward. Tango applies the principle of synthetic lethality to explore cancer therapies, targeting critical areas, including tumor suppressor gene loss.
Tango Therapeutics (TNGX) announced significant advancements in cancer treatments, including the start of a Phase 1/2 trial for TNG908, a PRMT5 inhibitor, now open for enrollment targeting MTAP-deleted tumors. The company also declared TNG462 and TNG260 as development candidates for similar applications. With a robust cash position of $450 million, Tango aims to progress its pipeline into late 2024. Financially, Tango reported a net loss of $25.2 million for Q1 2022, with research and development expenses rising to $24.3 million compared to $15 million a year prior.
FAQ
What is the current stock price of Tango Therapeutics (TNGX)?
What is the market cap of Tango Therapeutics (TNGX)?
